TRS23 Antibody

What is TRS23 and its role in the TRAPP complex?

TRS23 (Trs23p in yeast, TRAPPC4 in humans) is an essential core component of the highly conserved Transport Protein Particle (TRAPP) complexes, which function as key membrane trafficking regulators. TRS23/TRAPPC4 is found in both TRAPP I and TRAPP II/III complexes and plays a crucial role in their structural integrity .

The protein contains an important SMS domain that appears to be responsible for the in vitro appearance of TRAPP I in Saccharomyces cerevisiae . Functionally, TRS23 contributes to the guanine nucleotide exchange factor (GEF) activity directed toward Ypt1p (Rab1 in mammals), which is essential for vesicular transport . The core TRAPP complex containing TRS23 links two Bet3p-containing subcomplexes, thereby forming the functional TRAPP holocomplex necessary for proper membrane trafficking .

How should researchers validate TRS23 antibodies for experimental use?

When validating TRS23 antibodies for research applications, implement a multi-step validation strategy:

• Western blot analysis: Confirm antibody specificity by detecting a band at the expected molecular weight (~23 kDa for yeast Trs23p or ~24 kDa for human TRAPPC4). Compare wild-type cells with TRS23/TRAPPC4 knockout or knockdown samples as negative controls.

• Immunoprecipitation validation: Perform IP-Western experiments where TRS23 is immunoprecipitated and blotted for other known TRAPP complex components such as Bet3p/TRAPPC3, Bet5p/TRAPPC1, or Trs33p/TRAPPC6 .

• Subcellular localization: Confirm proper localization pattern through immunofluorescence microscopy. TRS23/TRAPPC4 typically shows a punctate Golgi-like distribution pattern .

• Cross-reactivity assessment: If working with humanized yeast models, test antibody cross-reactivity between yeast Trs23p and human TRAPPC4 to ensure specificity when studying both proteins in the same system .

What expression patterns and subcellular localization should be expected when using TRS23 antibodies?

When using TRS23 antibodies for localization studies, researchers should expect:

• Subcellular distribution: TRS23/TRAPPC4 primarily localizes to the Golgi apparatus, appearing as punctate structures in fluorescence microscopy. In yeast, it may also associate with ER-Golgi intermediate compartments .

• Co-localization patterns: Expect co-localization with other TRAPP complex proteins and partial overlap with Golgi markers such as mannosidase II .

• Fractionation profile: In biochemical fractionation experiments, TRS23/TRAPPC4 should be detected in membrane fractions corresponding to the early Golgi and ER-Golgi intermediate compartments. In density gradient centrifugation, it typically co-fractionates with Golgi markers .

• Salt-dependent distribution: At physiological salt concentrations, TRS23/TRAPPC4 appears in both TRAPP I and high molecular weight fractions containing TRAPP II/III. Increasing salt concentration resolves the high molecular weight peak into separate TRAPP II and III peaks .

What are the key differences between yeast Trs23p and human TRAPPC4 antibody applications?

Despite the orthologous relationship between yeast Trs23p and human TRAPPC4, several important differences affect antibody applications:

• Structural domains: Human TRAPPC4 shares only 29% identity/44% similarity with yeast Trs23p . This low homology means antibodies may not cross-react between species, necessitating species-specific antibodies.

• Complex composition: In mammalian cells, only one TRAPP complex has been reported, containing homologs of both yeast TRAPP II and III-specific proteins . This affects co-immunoprecipitation strategies when using TRS23/TRAPPC4 antibodies.

• Saccharomycotina-specific domain: Yeast Trs23p contains a Saccharomycotina-specific domain that is absent in human TRAPPC4. Antibodies directed against this domain would not be useful in human studies .

• Experimental consistency: When comparing data between yeast and human systems, researchers should note that deletion of the Saccharomycotina-specific domain (SMS) of Trs23p destabilizes TRAPP I in vitro but does not affect TRAPP II or III .

How can TRS23 antibodies be used to differentiate between TRAPP I, II, and III complexes?

Distinguishing between TRAPP complexes requires sophisticated techniques using TRS23 antibodies:

• Size exclusion chromatography with immunoblotting:

  • TRAPP I: ~300 kDa

  • TRAPP II: ~1000 kDa

  • TRAPP III: ~500 kDa

  After fractionation, probe with anti-TRS23 antibodies along with complex-specific markers:

  • For TRAPP II specificity: Additional detection of TRAPPC9/Trs120p and TRAPPC10/Trs130p

  • For TRAPP III specificity: Detection of TRAPPC8/Trs85p

• Salt-dependent complex resolution:

  • At physiological salt concentrations, only TRAPP I and a high molecular weight peak are detected

  • As salt concentration increases, the high molecular weight peak resolves into TRAPP II and III

  • This biochemical behavior can be leveraged to study complex dynamics using TRS23 antibodies

• Differential co-immunoprecipitation:

  • Immunoprecipitate with TRS23 antibodies under varying salt conditions

  • Identify complex-specific interacting partners:

    • TRAPP I: Core components only (TRAPPC1-6)

    • TRAPP II: Contains additional TRAPPC9/10

    • TRAPP III: Contains TRAPPC8 and metazoan-specific TRAPPC11/12/13

What methodological approaches should be used when studying TRS23 mutations in disease models?

To effectively study TRS23/TRAPPC4 mutations in disease models:

• Humanized yeast systems:

  • Create yeast strains where TRS23 is replaced with human TRAPPC4 using CRISPR/Cas9 editing

  • Introduce disease-associated mutations into the humanized TRAPPC4

  • Assess phenotypes including growth, membrane trafficking, and autophagy

  • This approach is particularly valuable when patient-derived cells are unavailable

• Functional complementation assays:

  • In yeast systems, test if human TRAPPC4 variants can complement TRS23 deletion

  • Use counterselection with 5-fluoroorotic acid (5-FOA) to assess functional rescue

  • Quantify rescue efficiency through growth rate analysis and microscopy

• Domain-specific mutation analysis:

  • Target specific domains of TRS23/TRAPPC4:

    • SMS domain mutations affect TRAPP I stability but not TRAPP II/III

    • C-terminal mutations (e.g., trs23Δ99C) affect protein solubility and integration into TRAPP

    • Key point mutations (e.g., MPR/AWS) can severely impact function

• Biochemical consequence assessment:

  • Measure GEF activity toward Ypt1p/Rab1 in vitro and in vivo

  • Evaluate complex assembly using size exclusion chromatography

  • Quantify protein stability through pulse-chase experiments

  • Assess subcellular localization patterns of mutant proteins

What are the optimal protocols for studying TRS23-dependent membrane trafficking defects?

To investigate membrane trafficking defects using TRS23 antibodies:

• In vitro transport assays:

  • Prepare cytosol fractions from wild-type and TRS23-mutant cells

  • Measure ER-to-Golgi transport using radiolabeled cargo proteins

  • Complement mutant cytosol with purified TRS23/TRAPPC4 protein to confirm specificity

  • Use TRS23 antibodies to immunodeplete the protein and confirm its requirement

• Autophagy assessment:

  • Monitor autophagy flux in TRS23-mutant cells:

    • Western blotting for LC3-I to LC3-II conversion

    • Normalize to tubulin signal

    • Induce autophagy using Earl's balanced salt solution (EBSS)

    • Compare kinetics at 0h, 1h, and 2h timepoints

• Golgi morphology analysis:

  • Use anti-mannosidase II as a Golgi marker in immunofluorescence

  • Co-stain with TRS23 antibodies to assess co-localization

  • Quantify Golgi fragmentation and dispersal in TRS23-mutant cells

  • Perform rescue experiments with wild-type protein expression

• Live-cell trafficking assays:

  • Track fluorescently-labeled cargo proteins in real-time

  • Quantify trafficking kinetics using time-lapse microscopy

  • Compare wild-type, TRS23-mutant, and rescued cells

  • Correlate defects with biochemical complex assembly data

How do different experimental conditions affect TRS23 antibody performance in complex isolation?

TRS23 antibody performance is significantly influenced by experimental conditions:

• Salt concentration effects:

  • Physiological salt (~150mM NaCl): TRAPP I and high molecular weight complexes

  • Increased salt (>250mM NaCl): Resolution of high molecular weight peak into TRAPP II and III

  • High salt (>500mM NaCl): Further dissociation into subcomplexes

  • Recommendation: Include salt titration series in fractionation experiments

• Detergent selection impact:

  Detergent	TRAPP I Detection	TRAPP II/III Detection	Recommended Concentration
  Triton X-100	Excellent	Good	1%
  NP-40	Good	Good	0.5-1%
  Digitonin	Poor	Excellent	1-2%
  CHAPS	Moderate	Good	1%

• Buffer composition considerations:

  • Include DTT (1mM) to maintain protein stability

  • EDTA (0.5mM) helps preserve complex integrity

  • Complete protease inhibitors are essential to prevent degradation

  • Tris buffer (50mM, pH 7.2) provides optimal results

• Temperature sensitivity:

  • TRS23 mutants may display conditional phenotypes (e.g., cold sensitivity)

  • Perform experiments at both permissive (30°C) and restrictive (15°C) temperatures

  • Some mutations (e.g., trs23 MPR/AWS) show severe cold-sensitive phenotypes that affect antibody detection patterns

What controls should be included when using TRS23 antibodies in co-immunoprecipitation studies?

For rigorous co-immunoprecipitation studies with TRS23 antibodies:

• Essential controls:

  • Input sample (5-10% of starting material)

  • Non-immune IgG control (same species as TRS23 antibody)

  • IP from TRS23-depleted or knockout cells

  • Reciprocal IP using antibodies against known interacting partners

  • Beads-only control without primary antibody

• Validation approaches:

  • Confirm expected interactions with core TRAPP components:

    • TRAPPC1/Bet5p

    • TRAPPC2/Trs20p

    • TRAPPC3/Bet3p

    • TRAPPC6A/B/Trs33p

  • Test interactions under different salt concentrations to distinguish stable vs. transient interactions

  • Verify complex-specific interactions (e.g., TRAPPC9/10 for TRAPP II, TRAPPC8 for TRAPP III)

• Troubleshooting strategies:

  • If interactions appear weak, crosslinking before lysis can stabilize transient complexes

  • For membrane-associated complexes, include appropriate detergents in lysis buffer

  • When studying mutant proteins, adjust IP conditions based on the mutation's effect on protein stability

What are the recommended techniques for visualizing TRS23 in cellular compartments?

For optimal visualization of TRS23/TRAPPC4 in cells:

• Immunofluorescence microscopy protocol:

  • Fixation: 4% paraformaldehyde (10 min) followed by methanol (-20°C, 5 min)

  • Permeabilization: 0.1% Triton X-100 in PBS (5 min)

  • Blocking: 3% BSA in PBS (30 min)

  • Primary antibody: Anti-TRS23/TRAPPC4 (1:100-1:500 dilution)

  • Co-staining markers:

    • Anti-mannosidase II for Golgi (1:500)

    • ER markers (anti-PDI or anti-Sec61)

    • Nuclear staining with Hoechst 33342 (1:2000)

• Super-resolution microscopy considerations:

  • For detailed localization, STED or STORM microscopy provides superior resolution

  • Secondary antibodies should be conjugated to bright, photostable fluorophores

  • Consider dual-color super-resolution to precisely map TRS23 relative to organelle markers

• Live-cell imaging approaches:

  • If antibody-based detection is insufficient, consider fluorescent protein tagging

  • Validate that tags do not disrupt TRS23 function or localization

  • Use CRISPR/Cas9 to introduce tags at endogenous loci for physiological expression levels

How can researchers use TRS23 antibodies to study TRAPP complex assembly defects?

To investigate TRAPP complex assembly defects:

• Sucrose gradient analysis:

  • Prepare cell lysates in physiological buffer (150mM NaCl, 50mM Tris pH 7.2)

  • Fractionate using 10-50% sucrose gradients

  • Collect fractions and perform Western blotting with TRS23 antibodies

  • Compare fractionation profiles between wild-type and mutant samples

  • Look for shifts from high molecular weight to smaller subcomplexes

• Pulse-chase analysis of complex assembly:

  • Metabolically label cells with 35S-methionine/cysteine

  • Chase with excess unlabeled amino acids

  • Immunoprecipitate with TRS23 antibodies at different timepoints

  • Analyze co-precipitating TRAPP components

  • This reveals the kinetics of complex assembly and stability

• Cross-linking mass spectrometry:

  • Cross-link cellular proteins using membrane-permeable cross-linkers

  • Immunoprecipitate with TRS23 antibodies

  • Perform mass spectrometry to identify cross-linked peptides

  • Map the molecular architecture of TRAPP complexes

  • Compare wild-type and mutant assembly patterns

• In vitro reconstitution:

  • Express and purify recombinant TRAPP components

  • Combine proteins in different orders and salt concentrations

  • Analyze complex formation by native PAGE and Western blotting

  • Use TRS23 antibodies to track incorporation into higher-order assemblies

What approaches can detect TRS23 post-translational modifications affecting TRAPP function?

For studying post-translational modifications (PTMs) of TRS23/TRAPPC4:

• Phosphorylation detection methods:

  • Phospho-specific antibodies if available

  • Phos-tag SDS-PAGE followed by Western blotting with TRS23 antibodies

  • Immunoprecipitate with TRS23 antibodies followed by phospho-specific staining

  • Mass spectrometry to map precise phosphorylation sites

• Ubiquitination and SUMOylation analysis:

  • Immunoprecipitate under denaturing conditions to preserve modifications

  • Western blot for ubiquitin or SUMO conjugates

  • For confirmation, express tagged ubiquitin/SUMO constructs

  • Compare modification patterns between wild-type and disease-associated mutants

• Protocol for detecting multiple PTMs:

  • Immunoprecipitate TRS23 from cells treated with/without stress conditions

  • Split sample for parallel analysis of different modifications

  • Correlate modifications with functional outcomes:

    • Complex assembly (size exclusion chromatography)

    • GEF activity (in vitro nucleotide exchange assays)

    • Subcellular localization (immunofluorescence microscopy)

How should researchers address non-specific binding when using TRS23 antibodies?

To minimize non-specific binding in TRS23 antibody applications:

• Western blot optimization:

  • Increase blocking time/concentration (5% BSA or milk, 1-2 hours)

  • Titrate primary antibody concentration (typically 1:1000-1:5000)

  • Include 0.1-0.3% Tween-20 in wash buffers

  • For persistent background, try alternative blocking agents (casein, commercial blockers)

  • Consider overnight primary antibody incubation at 4°C

• Immunoprecipitation specificity enhancement:

  • Pre-clear lysates with Protein A/G beads before adding antibody

  • Include competing proteins (BSA, gelatin) in wash buffers

  • Increase number and duration of washes

  • Use crosslinking to attach antibodies to beads, preventing heavy chain contamination

  • Validate results with multiple antibodies targeting different epitopes of TRS23

• Immunofluorescence background reduction:

  • Extend blocking time (1-2 hours at room temperature)

  • Include 0.1-0.3% Triton X-100 in antibody dilution buffers

  • Use Sudan Black B (0.1% in 70% ethanol) to reduce autofluorescence

  • Filter antibody solutions before use (0.22μm filter)

  • Consider using highly cross-adsorbed secondary antibodies

What are the key considerations when designing experiments to study TRS23 interactions with other TRAPP components?

When investigating TRS23 interactions with other TRAPP components:

How do different fixation methods affect TRS23 antibody performance in microscopy?

The choice of fixation protocol significantly impacts TRS23 antibody performance in microscopy:

• Comparative analysis of fixation methods:

  Fixation Method	Epitope Preservation	Membrane Integrity	Recommended For
  4% PFA (10 min)	Good	Excellent	General localization
  Methanol (-20°C, 5 min)	Variable	Good for permeabilization	Detecting protein interactions
  PFA + Methanol (sequential)	Very good	Excellent	Detailed structural studies
  Glutaraldehyde (0.1-0.5%)	Excellent	Excellent	Ultrastructural studies
  Acetone (-20°C, 5 min)	Variable	Fair	Quick screening

• Optimization recommendations:

  • Test multiple fixation protocols with your specific TRS23 antibody

  • For co-localization studies, ensure fixation preserves both TRS23 and marker proteins

  • When studying membrane-associated TRAPP complexes, avoid harsh detergents that disrupt membrane morphology

  • For super-resolution microscopy, fixation quality is critical - consider testing glutaraldehyde mixtures

• Antigen retrieval options:

  • Citrate buffer (pH 6.0, 95°C, 10 min) can recover some epitopes after PFA fixation

  • Trypsin treatment (0.05%, 5 min) may expose masked epitopes

  • SDS treatment (0.5%, 5 min) can improve access to some epitopes

How can TRS23 antibodies be used to characterize TRAPPopathies?

TRS23/TRAPPC4 antibodies provide valuable tools for studying TRAPP-related disorders:

• Patient sample analysis protocol:

  • Isolate primary fibroblasts from patients with TRAPP mutations

  • Compare TRS23/TRAPPC4 levels, complex assembly, and subcellular distribution

  • Assess membrane trafficking using established cargo proteins

  • Evaluate autophagy by monitoring LC3 processing in response to EBSS treatment

• Golgi morphology analysis in disease models:

  • Use TRS23 antibodies alongside Golgi markers (mannosidase II)

  • Quantify Golgi fragmentation, dispersal, or other morphological changes

  • Compare results between patient-derived cells and controls

  • Perform rescue experiments with wild-type TRAPP proteins

• Functional complementation strategy:

  • Determine if wild-type TRS23/TRAPPC4 can rescue defects in cells with mutations in other TRAPP components

  • Utilize humanized yeast models to test disease-causing mutations

  • Assess if mutation-specific defects can be bypassed by overexpression of interacting partners

  • This approach helps position different TRAPP components in functional pathways

What is the recommended workflow for validating novel TRS23 mutations identified in patients?

For validating novel TRS23/TRAPPC4 mutations:

• Comprehensive validation workflow:

  • Sequence verification in multiple samples/family members

  • In silico pathogenicity prediction using multiple algorithms

  • Evolutionary conservation analysis across species

  • Structural modeling to predict impact on protein folding or interactions

  • Functional testing in cellular and animal models

• Humanized yeast model validation:

  • Replace yeast TRS23 with human TRAPPC4 using CRISPR/Cas9

  • Introduce patient mutations into the humanized gene

  • Assess growth phenotypes under various conditions

  • Monitor membrane trafficking and autophagy

  • Compare with results from patient-derived cells when available

• Biochemical characterization:

  • Express mutant proteins in recombinant systems

  • Analyze protein stability, solubility, and complex formation

  • Measure GEF activity toward Ypt1p/Rab1

  • Determine if mutations affect specific protein-protein interactions

  • Compare with known disease-causing mutations as benchmarks